Literature DB >> 33741009

Assessing the quality of information provided on websites selling Kratom (Mitragyna speciosa) to consumers in Canada.

Jeremy Y Ng1, Muhammad Ans2, Amn Marwaha2.   

Abstract

BACKGROUND: Amid a Canadian opioid crisis, many have turned to natural health products, such as kratom (Mitragyna speciosa), to manage their opioid withdrawal. Kratom has also been reported to relieve anxiety, improve stamina, and heighten physical performance. Given that kratom is not authorized for sale by Health Canada, many have turned to online retailers to purchase kratom due to its easy accessibility online. This study investigated the quality of consumer health information provided on the websites of online vendors selling kratom to consumers in Canada.
METHODS: Following searches on Google.ca using search terms designed to simulate the information-seeking behaviour of a typical patient-user online, eligible websites were assessed using the 16-question DISCERN instrument, a tool designed to assess the quality of consumer health information. Searches were conducted on March 27, 2020 and only websites presenting information in English were included.
RESULTS: A total of 200 webpages were identified; after screening based on eligibility criteria and combining different webpages that belonged to the same website, 51 websites were found to be eligible. The mean summed DISCERN score across all 51 websites was 36.95 (SD = 2.44) out of 75, which reflects poor quality consumer health information across the subset of websites. The overall quality of websites was poor, as 78% (n = 40) of vendors received a score of 2 or less out of 5.
CONCLUSIONS: Individuals who seek information about kratom online are frequently exposed to poor quality consumer health information. Those looking to purchase kratom online are not provided with the critical information necessary to make an informed decision regarding its use, such as the complete details about the risks and side effects or a description of how kratom affects the body. Given the growing interest in kratom, knowledge of the quality of information available can lead to improved dialogue between healthcare providers and patients.

Entities:  

Keywords:  DISCERN; Healthcare professionals; Herbal; Kratom; Mitragyna speciosa; Natural health products; Online vendor

Year:  2021        PMID: 33741009     DOI: 10.1186/s13011-021-00361-2

Source DB:  PubMed          Journal:  Subst Abuse Treat Prev Policy        ISSN: 1747-597X


  19 in total

1.  Characteristics of deaths associated with kratom use.

Authors:  John M Corkery; Peter Streete; Hugh Claridge; Christine Goodair; Duccio Papanti; Laura Orsolini; Fabrizio Schifano; Kanav Sikka; Sophie Körber; Amy Hendricks
Journal:  J Psychopharmacol       Date:  2019-08-20       Impact factor: 4.153

2.  Kratom, an Emerging Drug of Abuse: A Case Report of Overdose and Management of Withdrawal.

Authors:  Jack Diep; David Tian Chin; Somdatta Gupta; Faraz Syed; Ming Xiong; Jianguo Cheng
Journal:  A A Pract       Date:  2018-04-15

3.  Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy.

Authors:  Shyam H Kamble; Francisco León; Tamara I King; Erin C Berthold; Carolina Lopera-Londoño; Kanumuri Siva Rama Raju; Aidan J Hampson; Abhisheak Sharma; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-31

4.  Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms.

Authors:  Darshan Singh; Suresh Narayanan; Christian P Müller; Marc T Swogger; Azlan Abdul Rahim; Mohammad Farris Iman Leong Bin Abdullah; Balasingam K Vicknasingam
Journal:  J Psychoactive Drugs       Date:  2018-08-28

5.  Kratom Withdrawal: A Systematic Review with Case Series.

Authors:  Cornel N Stanciu; Samantha A Gnanasegaram; Saeed Ahmed; Thomas Penders
Journal:  J Psychoactive Drugs       Date:  2019-01-05

6.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

Review 7.  The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth.

Authors:  E J Shellard
Journal:  Bull Narc       Date:  1974 Apr-Jun

Review 8.  Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom.

Authors:  Dimy Fluyau; Neelambika Revadigar
Journal:  Front Psychiatry       Date:  2017-04-24       Impact factor: 4.157

9.  Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.

Authors:  Alicia G Lydecker; Abhisheak Sharma; Christopher R McCurdy; Bonnie A Avery; Kavita M Babu; Edward W Boyer
Journal:  J Med Toxicol       Date:  2016-10-17

10.  Exploring consumer and pharmacist views on the professional role of the pharmacist with respect to natural health products: a study of focus groups.

Authors:  Della Kwan; Heather S Boon; Kristine Hirschkorn; Sandy Welsh; Tannis Jurgens; Lynda Eccott; Shirley Heschuk; Glenn G Griener; Jillian C Cohen-Kohler
Journal:  BMC Complement Altern Med       Date:  2008-07-14       Impact factor: 3.659

View more
  2 in total

1.  Kratom exposures managed by the British Columbia poison centre, 2012-2019: a descriptive analysis.

Authors:  Noah Reich; Grazia Salvo; Dennis Leong; Victoria Wan; Tom Kosatsky
Journal:  CMAJ Open       Date:  2022-08-16

2.  Dietary and herbal supplements for fatigue: A quality assessment of online consumer health information.

Authors:  Jeremy Y Ng; Catherine Jiayi Zhang; Saad Ahmed
Journal:  Integr Med Res       Date:  2021-05-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.